Intestinal Research

Original Articles

Anti-integrin αvβ6 autoantibody in patients with ulcerative colitis after proctocolectomy: a cross-sectional study in Japan: Tsuyoshi Yanagida, Yu Nishida, Yumie Kobayashi, Rieko Nakata, Shuhei Hosomi, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Yasuhiro Fujiwara; Received October 22, 2024 Accepted February 18, 2025 Published online April 29, 2025; DOI: https://doi.org/10.5217/ir.2024.00170 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Pouchitis is a common complication in patients with ulcerative colitis (UC) following colectomy with ileal pouch-anal anastomosis (IPAA). Recent studies have identified a novel autoantibody against integrin αvβ6 in patients with UC, correlated with disease activity. This study aimed to assess the association between serum anti-integrin αvβ6 antibody levels and pouch inflammation in patients with postoperative UC.
Methods
Serum anti-integrin αvβ6 antibodies were measured using enzyme-linked immunosorbent assay in patients after IPAA, patients with UC, and controls.
Results
We examined sera from 71 subjects, including 28 patients who underwent IPAA, 23 controls, and 20 patients with mild and moderate-to-severe UC. Post-IPAA, patients with UC had higher median anti-integrin αvβ6 levels than that of controls (P<0.001) but lower than that of patients with active UC (P=0.001). Patients with pouchitis had higher antibody levels than those without (P=0.047). The receiver operating characteristics curve for anti-integrin αvβ6 showed an area under the curve of 0.724. The pouchitis activity index endoscopic sub-score was correlated with antibody levels (r= 0.48, P=0.011).
Conclusions
Serum anti-integrin αvβ6 antibody levels remain elevated in patients with UC even after total colectomy, and were significantly higher in patients with pouchitis than in those without. This antibody could be a novel and useful biomarker for the diagnosis of pouchitis and assessment of disease activity.

Citations

Citations to this article as recorded by

Clinical Value of Anti-Integrin αvβ6 Antibody Serum-Level Measurement in Inflammatory Bowel Diseases
Dorottya Angyal, Fruzsina Balogh, Lorant Gonczi, Livia Lontai, Janos P. Kosa, Nora Garam, Peter L. Lakatos, Akos Ilias
Journal of Clinical Medicine.2026; 15(3): 948. CrossRef

2,876 View
347 Download
1 Web of Science
1 Crossref

IBD

Tuberculosis risk in patients with Crohn’s disease on biologics: a retrospective analysis of the Japanese Medical Claims Database: Koji Fujimoto, Shuhei Hosomi, Yumie Kobayashi, Rieko Nakata, Yu Nishida, Masaki Ominami, Yuji Nadatani, Shusei Fukunaga, Koji Otani, Fumio Tanaka, Satoko Ohfuji, Yasuhiro Fujiwara; Intest Res 2025;23(3):309-317. Published online August 19, 2024; DOI: https://doi.org/10.5217/ir.2024.00076

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Treatment using tumor necrosis factor-α (TNF-α) inhibitors is one of the risk factors for active tuberculosis (TB) in patients with Crohn’s disease (CD). Biologics, such as ustekinumab (UST) and vedolizumab (VDZ), are less likely to cause opportunistic infections. However, large-scale studies for active TB and biologics other than TNF-α inhibitors are limited. We aimed to investigate the association between biologics and active TB utilizing a Japanese medical claims database.
Methods
We analyzed retrospectively the association of the risk of active TB development with treatment using TNF-α inhibitors and other biologics (UST and VDZ) in patients with CD using the Japanese Medical Data Vision (MDV) database between April 2008 and June 2022. The durations of each biologic and biologic-free treatment were calculated for each patient. Univariate and multivariate analyses were performed using the Cox proportional hazards model, with the utilization of biologics considered as time-dependent covariates.
Results
We included 28,811 patients with CD in MDV database. Finally, 17,169 patients were analyzed. In total, 7,064 patients were categorized as biologic-naïve, while 10,105 were classified as biologic-experienced. Seventeen patients developed active TB, including 7 on infliximab, 5 on adalimumab, and 5 on no biologics. None of the patients treated with UST and VDZ developed active TB. Multivariate analysis suggested that TNF-α inhibitors were the risk factors for active TB (hazard ratio, 3.66; P= 0.020).
Conclusions
TNF-α inhibitors, but not UST or VDZ, are risk factors for active TB in Japanese patients with CD.

Citations

Citations to this article as recorded by

Research Communication: Risk of Tuberculosis With Advanced Therapies in 20,705 Patients With Inflammatory Bowel Diseases in Low Incidence Regions—A U.S. Claims‐Based Study
Dhruv Ahuja, Kuan‐Hung Yeh, Sagar B. Patel, Soo‐kyung Park, Ronghui Xu, Siddharth Singh
Alimentary Pharmacology & Therapeutics.2026; 63(6): 885. CrossRef
Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team
Nanae Tsuruoka, Hironobu Takedomi, Yasuhisa Sakata, Shin Fujioka, Ryosuke Sakemi, Shinya Ashizuka, Nobuaki Nishimata, Kazumi Inaba, Shuji Kanmura, Tetsu Kinjo, Yoki Furuta, Shinichiro Yoshioka, Shojiro Yamamoto, Ayako Takamori, Fumihito Hirai, Motohiro Es
Journal of Gastroenterology.2026;[Epub] CrossRef
Subacute respiratory symptoms in a patient with Crohn’s disease and ankylosing spondylitis
Doohyuck Lee, Kwangwoo Nam, Ho Jin Yong, Juntae Kim, Miil Kang
The Korean Journal of Internal Medicine.2026;[Epub] CrossRef
Risk of tuberculosis disease among patients with inflammatory bowel disease and inflammatory rheumatic disease treated with biologics in Denmark: a nationwide cohort study
Christian Kraef, Anne Ahrens Østergaard, Troels Lillebaek, Pernille Ravn, Andreas Fløe, Lone Larsen, Ada Colic, Inge Petersen, Isik Somuncu Johansen
Clinical Microbiology and Infection.2025;[Epub] CrossRef
Assessing tuberculosis risk in Crohn’s disease patients receiving biologic therapies: real-world insights from Japan
Jung Won Lee, Yoo Min Han
Intestinal Research.2025; 23(3): 231. CrossRef
Practices and perceptions of 5-aminosalicylic acid use in Crohn’s disease: a nationwide survey of physicians in Korea by KASID Guidelines Taskforce Team
June Hwa Bae, Seung Yong Shin, Dong Hyun Kim, Seung Min Hong, Eun Mi Song, Ji Eun Kim, Young Joo Yang, Jiyoung Yoon, Sang-Bum Kang, Eun Soo Kim, Sung Eun Kim, Seong-Jung Kim, Jun Lee, Soo-Young Na, Soo Jung Park, Sang Hyoung Park, Won Moon, Sung-Ae Jung
Intestinal Research.2025; 23(4): 491. CrossRef
Safety assessment of ustekinumab in inflammatory bowel disease: a real-world analysis based on the FDA adverse event reporting system (FAERS)
Likang Xu, Zhenkai Huang, Gong Chen, Chao Sun, Yang Yu, Sujun Gao
European Journal of Medical Research.2025;[Epub] CrossRef

10,608 View
273 Download
6 Web of Science
7 Crossref

First
Prev
Page of 1
Next
Last

Search